TScan Therapeutics (TCRX) Non-Current Deffered Revenue (2020 - 2025)

TScan Therapeutics (TCRX) has 5 years of Non-Current Deffered Revenue data on file, last reported at $501000.0 in Q1 2025.

• On a quarterly basis, Non-Current Deffered Revenue fell 89.47% year-over-year to $501000.0 in Q1 2025; TTM through Mar 2025 was $501000.0, a 89.47% decrease from a year earlier, with the FY2024 full-year figure at $1.2 million, down 77.84% from the prior year.
• Non-Current Deffered Revenue for Q1 2025 stood at $501000.0, down from $1.2 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for TCRX reached as high as $7.8 million in Q3 2023 and fell as low as $501000.0 in Q1 2025.
• Historically, Non-Current Deffered Revenue has averaged $4.0 million across 4 years, with a median of $4.0 million in 2024.
• Across the five-year window, Non-Current Deffered Revenue sank 48.26% in 2024 and plunged 89.47% in 2025, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $1.5 million in 2021, then soared by 275.55% to $5.6 million in 2023, then slumped by 77.84% to $1.2 million in 2024, then plunged by 59.79% to $501000.0 in 2025.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $501000.0 in Q1 2025, $1.2 million in Q4 2024, and $3.7 million in Q3 2024.